S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Price, News & Analysis

$2.17
+0.24 (+12.44%)
(As of 03/27/2024 ET)
Today's Range
$1.93
$2.17
50-Day Range
$1.68
$2.43
52-Week Range
$1.24
$12.75
Volume
469,537 shs
Average Volume
338,437 shs
Market Capitalization
$19.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.25

Fortress Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,800.9% Upside
$41.25 Price Target
Short Interest
Bearish
12.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Fortress Biotech in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$119,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.28 out of 5 stars

Medical Sector

332nd out of 939 stocks

Pharmaceutical Preparations Industry

150th out of 436 stocks

FBIO stock logo

About Fortress Biotech Stock (NASDAQ:FBIO)

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

FBIO Stock Price History

FBIO Stock News Headlines

Fortress Biotech (FBIO) Scheduled to Post Earnings on Thursday
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Fortress Biotech, Inc. (NASDAQ:FBIO) Short Interest Update
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Why Fortress Biotech Shares Are Tumbling Today
See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
187
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.25
High Stock Price Target
$75.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,800.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-86,570,000.00
Pretax Margin
-224.80%

Debt

Sales & Book Value

Annual Sales
$75.74 million
Book Value
$6.79 per share

Miscellaneous

Free Float
6,537,000
Market Cap
$19.40 million
Optionable
Optionable
Beta
1.52
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 69)
    Executive Chairman, President & CEO
    Comp: $942.78k
  • Mr. Michael S. Weiss Esq. (Age 58)
    Vice Chairman & Executive Vice Chairman of Strategic Development
    Comp: $167.92k
  • Mr. David Jin (Age 33)
    CFO & Head of Corporate Development
    Comp: $976.96k
  • Dr. George C. Avgerinos (Age 70)
    Senior Vice President of Biologics Operations
    Comp: $386.49k
  • Mr. Samuel Berry
    General Counsel & Corporate Secretary

FBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings
or view top-rated stocks.

What is Fortress Biotech's stock price target for 2024?

5 Wall Street analysts have issued 12 month target prices for Fortress Biotech's stock. Their FBIO share price targets range from $5.00 to $75.00. On average, they anticipate the company's share price to reach $41.25 in the next year. This suggests a possible upside of 1,800.9% from the stock's current price.
View analysts price targets for FBIO
or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2024?

Fortress Biotech's stock was trading at $3.01 at the beginning of the year. Since then, FBIO shares have decreased by 27.9% and is now trading at $2.17.
View the best growth stocks for 2024 here
.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,730,000 shares, an increase of 12.3% from the February 29th total of 1,540,000 shares. Based on an average trading volume of 500,600 shares, the short-interest ratio is currently 3.5 days. Approximately 13.0% of the shares of the stock are short sold.
View Fortress Biotech's Short Interest
.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our FBIO earnings forecast
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) announced its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by $0.90. The biopharmaceutical company had revenue of $21.09 million for the quarter, compared to the consensus estimate of $18.41 million. Fortress Biotech had a negative net margin of 96.71% and a negative trailing twelve-month return on equity of 770.86%.

When did Fortress Biotech's stock split?

Fortress Biotech's stock reverse split before market open on Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.67%), Nantahala Capital Management LLC (4.17%), Vanguard Group Inc. (3.96%), Vanguard Group Inc. (3.96%), Shikiar Asset Management Inc. (2.05%) and PVG Asset Management Corp (1.47%). Insiders that own company stock include Lindsay A Md Rosenwald and Michael S Weiss.
View institutional ownership trends
.

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FBIO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners